Skip to main content

Table 1 Patient characteristics

From: EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

Characteristic

Patients (n = 107)

 

No.

(%)

Age, Years

  

   Median

62

   Range

38-82

Gender

  

   Female

49

(46)

   Male

58

(54)

ECOG performance status

  

   0

55

(51)

   1

42

(39)

   2

10

(10)

No. of prior chemotherapy regimes for metastatic disease

  

   2

79

(74)

   3

27

(25)

   NA

1

(1)

Primary surgery for CRC

  

   Yes

97

(91)

   No

9

(8)

   NA

1

(1)

Pre-operative chemoradiation

  

   Yes

17

(16)

   No

88

(82)

   NA

2

(2)

Anatomic site

  

   Colon

40

(37)

   Rectosignoideum

36

(34)

   Rectum

39

(36)

   NA

3

(3)

No. of metastatic sites

  

   1-2

48

(45)

   3-5

57

(53)

   NA

1

(1)

No of cycles

   Median

6

   Range

1-18

Best response

   PR

20

(19)

   SD

35

(33)

   PD

31

(29)

   Clinical progression*

17

(16)

   NA

4

(4)

Worst Toxicity/Rash grade

   0

15

(14)

   1

41

(39)

   2

19

(18)

   3

11

(13)

   NA

25

(23)

  1. Legend; NA (not assessed), PR, partial response; SD, stable disease, PD progressive disease, * clinical progression (at investigators discretion) in patients who were treated with less than 3 series and consequently not evaluated according to RECIST.